1-3 of 3
Arthur P. Decillis, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 3937.
https://doi.org/10.1182/blood-2019-121736
Published: 2019
Journal Articles

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Jennifer R Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Arthur P. DeCillis, MD, MS, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Farrukh T Awan, MD, MS
Journal: Blood
Blood (2011) 118 (21): 2683.
https://doi.org/10.1182/blood.V118.21.2683.2683
Published: 2011
Journal Articles

Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript.

Neil P. Shah, MD, PhD, Susan Branford, Timothy P. Hughes, MD, John M. Nicoll, Arthur P. Decillis, MD, Charles L. Sawyers, MD.
Journal: Blood
Blood (2004) 104 (11): 1008.
https://doi.org/10.1182/blood.V104.11.1008.1008
Published: 2004